Actively Recruiting
CAR-T Immunotherapy Targeting CD19- ALL
Led by Shenzhen Geno-Immune Medical Institute · Updated on 2026-04-23
100
Participants Needed
3
Research Sites
230 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate safety and efficacy of a combination of 4th generation chimeric antigen receptor gene-modified T cells targeting CD19 negative ALL that express CD22, CD123, CD38, CD10, CD20 and TSLPR, as many patients developed CD19-negative disease after CD19 CART immunotherapy. Clinical response and development of a standardized lentiviral vector and cell production protocol will be investigated. This is a phase I/II trial enrolling patients from multiple clinical centers.
CONDITIONS
Official Title
CAR-T Immunotherapy Targeting CD19- ALL
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age older than 6 months
- Diagnosis of native CD19 negative B cell malignancies or relapse after CD19-CAR-T immunotherapy
- Malignant B cells expressing one or more of the following surface markers: CD22, CD123, CD38, CD10, CD20, or TSLPR
- Karnofsky Performance Status (KPS) score over 80 points with expected survival time more than 1 month
- Hemoglobin level greater than 80 g/L
- No contraindications to blood cell collection
You will not qualify if you...
- Presence of other active diseases that complicate assessment of patient response
- Uncontrolled bacterial, fungal, or viral infections
- Living with HIV infection
- Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection
- Pregnant or nursing mothers
- Systemic steroid use within one week before treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China, 510282
Actively Recruiting
2
Shenzhen Geno-immune Medical Institute
Shenzhen, Guangdong, China, 518000
Actively Recruiting
3
Zhongxi Children Hospital
Shijiazhuang, Hebei, China, 050006
Actively Recruiting
Research Team
L
Lung-Ji Chang, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here